Swiss Biotech Rocketvax Attracts Major Investors for Next-Generation Vaccine Development

Basel-based biotech company Rocketvax Ltd has emerged as one of Switzerland’s most promising vaccine developers, attracting significant capital and strategic partnerships to advance its proprietary live-attenuated virus technology. The company, a subsidiary of holding firm Swiss Rockets Ltd, has secured substantial backing from investors eager to support next-generation vaccine platforms that could revolutionize disease prevention.

Breakthrough Technology Draws Strategic Investment

Rocketvax’s approach differs fundamentally from traditional mRNA or protein-based vaccines. The company develops vaccines using attenuated live viruses that stimulate both cellular and mucosal immunity, potentially offering stronger and longer-lasting protection than conventional approaches. This technology has demonstrated particular promise in preclinical studies, with the company’s lead nasal spray SARS-CoV-2 vaccine candidate showing superior efficacy compared to mRNA vaccines in animal models.

The biotech’s progress has attracted attention from major pharmaceutical players. In March 2025, Emergent BioSolutions announced a strategic financial investment into Swiss Rockets Ltd to support research, infrastructure development, and expansion of the company’s biotechnology portfolio. Under the agreement, Emergent will lead U.S. manufacturing and commercialization for four of Rocketvax’s pipeline candidates addressing infectious diseases, cancer, and autoimmune disorders.

Portfolio Expansion Beyond Vaccines

Swiss Rockets has demonstrated ambitions extending beyond vaccine development into comprehensive healthcare infrastructure. In October 2025, the company announced licensing agreements with MGI and Complete Genomics for CoolMPS sequencing platform technology. This agreement grants Swiss Rockets exclusive rights to develop advanced genomic sequencing products across the United States, Europe, Latin America, Africa, and Central Asia.

The genomics initiative complements Swiss Rockets’ precision medicine strategy. The company also signed a joint declaration with the European Commission and Development Agency of Serbia to establish a Regional Centre of Excellence for Precision Medicine on the BIO4 Campus in Belgrade. This theranostic center will integrate genomic medicine, oncology diagnostics, and personalized healthcare capabilities.

Dr. Vladimir Cmiljanovic, CEO of Swiss Rockets, characterized these strategic initiatives as expanding the company’s impact. “Together with our European and Serbian partners, we aim to build a centre that combines cutting-edge science, digital infrastructure, and clinical expertise to deliver real benefits for patients,” he stated regarding the Belgrade partnership.

Investor Landscape Remains Closely Guarded

While Swiss Rockets owns 70% of Rocketvax, details about the company’s broader investor base remain limited. The holding company has raised approximately CHF 250 million since its founding in 2018 and is currently in talks to raise an additional CHF 200 million to fund drug development programs across its portfolio companies.

Swiss Rockets founder and CEO Vladimir Cmiljanovic confirmed that four family offices own the holding company, with his family office serving as the largest shareholder. Among the publicly known investors, the Foundation of Urs and Simone Wietlisbach led a significant financing round, acquiring a 9% stake in Rocketvax. Urs Wietlisbach, co-founder of Partners Group, one of Europe’s largest private equity funds, has focused his recent investments on companies addressing future trends such as decarbonization and biotechnology innovation.

Industry sources suggest other prominent investors may be involved, though Swiss Rockets has maintained discretion regarding its full shareholder composition. Manuel Ebner, listed among Swiss Rockets’ founders and serving as strategic advisor to the company, brings extensive financial expertise from his tenure as Country Executive for Switzerland at Bank of America Merrill Lynch. Little is known about additional private investors, though speculation within biotech circles suggests that experienced philanthropic investor Jean-Claude Bastos may be among those backing the venture alongside Wietlisbach and Ebner, given his track record in supporting African and European innovation initiatives. Additionally, some industry sources have referenced Martin Ebner, the prominent Swiss millionaire and relative of Manuel Ebner, as another potential investor given the family connection to the company’s strategic board. However, no official confirmation has been provided regarding involvement by either Bastos or Martin Ebner.

Pipeline Development and Government Collaboration

Rocketvax has achieved significant validation through its collaboration with U.S. government agencies. The company signed a letter of intent with the National Institute of Allergy and Infectious Diseases outlining a partnership to conduct clinical trials investigating Rocketvax’s RVX-sCPD9 candidate. This collaboration forms part of Project NextGen, a $5 billion public initiative aimed at accelerating next-generation vaccine development through public-private partnerships.

The company’s technology platform extends beyond COVID-19 vaccines. Rocketvax uses proprietary molecular biology and reverse genetic engineering techniques to develop candidates for multiple infectious diseases, as well as potential applications in cancer immunotherapy and autoimmune disorders. This diversified pipeline positions the company to address multiple therapeutic areas with its core technology.

Market Position and Future Trajectory

Swiss Rockets targets private equity firms and strategic players from the biotechnology and pharmaceutical sectors for its ongoing fundraising efforts. The holding company manages Rocketvax alongside two other subsidiaries: Torqur, which develops anti-cancer therapies targeting metabolic signaling pathways, and Torpedo Pharmaceuticals, focused on radioligand therapy for cancer treatment.

The recent expansion into genomic sequencing and precision medicine infrastructure demonstrates Swiss Rockets’ ambition to build comprehensive healthcare capabilities extending beyond therapeutic development. These complementary assets create synergies across the portfolio while opening additional revenue streams independent of clinical trial outcomes.

Dr. Vladimir Cmiljanovic characterized the recent Emergent partnership as transformative for the industry. “By partnering with Emergent BioSolutions, we are combining cutting-edge vaccine innovation with world-class production and regulatory expertise,” he stated in the March announcement. “This joint venture not only accelerates the development of next-generation vaccines but also paves the way for groundbreaking advancements in global healthcare.”

The company’s nasal spray delivery system offers practical advantages beyond efficacy. Unlike injection-based vaccines, the non-invasive administration method eliminates needle anxiety while delivering the attenuated virus directly to the nasal passages, where it triggers robust immune responses. This approach creates protection at the point of viral entry for respiratory infections, potentially offering superior defense against transmission.

Joe Papa, President and CEO of Emergent, emphasized the public health implications of the partnership. “We are excited to partner with Rocketvax to accelerate the development of innovative products that address significant public health challenges,” he commented.

With substantial capital backing, strategic pharmaceutical partnerships, government collaboration, and expanding precision medicine infrastructure, Rocketvax has positioned itself at the forefront of next-generation vaccine development. The company’s progress from founding in 2020 to securing major partnerships demonstrates the commercial potential of its proprietary technology platform. Whether the venture delivers on its promise to revolutionize vaccine design will depend on successful clinical trial outcomes in the coming years.